China Medical System Holdings (China Medical System Holdings) ROCE % : 7.75% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is China Medical System Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. China Medical System Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was 7.75%.

China Medical System Holdings ROCE % Historical Data

The historical data trend for China Medical System Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Medical System Holdings ROCE % Chart

China Medical System Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

25.74

27.39

27.65

25.50

18.89

China Medical System Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															24.83	28.90	23.38	29.30	7.75

China Medical System Holdings ROCE % Calculation

China Medical System Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	408.955	/	( ( (2546.515 - 412.683)	+	(2483.241 - 286.937) )	/ 2 )
	=	408.955	/	( (2133.832	+	2196.304)	/ 2 )
	=	408.955	/	2165.068
	=	18.89 %

China Medical System Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	172.606	/	( ( (2567.303 - 309.936)	+	(2483.241 - 286.937) )	/ 2 )
	=	172.606	/	( ( 2257.367	+	2196.304 )	/ 2 )
	=	172.606	/	2226.8355
	=	7.75 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

China Medical System Holdings (OTCPK:CHSYF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

China Medical System Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of China Medical System Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

China Medical System Holdings (China Medical System Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Medical System Holdings Ltd (OTCPK:CHSYF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

00867:Hong Kong 2M7C:Germany

Address

510 King’s Road, Unit 2106, 21st Floor, North Point, Island Place Tower, Hong Kong, HKG

Website

http://www.cms.net.cn

China Medical System Holdings Ltd is active in the healthcare segment. It is one of the leading China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil; Salofalk; Combizym; Ganfule Capsules; Xidakang; Hirudoid; and others. Geographically, it derives revenue from China.

China Medical System Holdings (China Medical System Holdings) Headlines

From GuruFocus

China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug

By ACN Newswire • 08-27-2023

China Medical System Holdings Ltd (CHSYF): A Deep Dive into its Upcoming Dividend

By GuruFocus Research • 09-11-2023

Gelonghui Reports CMS' Successful Phase III Study of Methylthioninium Chloride Enteric-coated Sustained-release Tablets

By ACN Newswire ACN Newswire • 12-20-2022